FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

May 19, 2017
by Alejandra Spangler

The FDA has now approved Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients who are cisplatin-ineligible diagnosed with locally advanced or metastatic urothelial carcinoma. Additionally, second-line treatment in patients who are platinum-ineligible and have disease progression during or following chemotherapy or within 12 months of neoadjuvant or adjuvant treatment has also been approved.  KEYTRUDA is the only Anti-PD-1 therapy showing superior overall survival compared to chemotherapy in patients with advanced urothelial carcinoma following platinum failure.

Click below to read Merck’s Press Release:

Merck Press Release

Share this page:Share on FacebookTweet about this on TwitterShare on Google+Share on TumblrShare on LinkedInEmail this to someone